Identifying the target NSCLC patient for maintenance therapy: An analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)†

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1534-1542

  Obasaju, C ^a   Bowman, L ^a   Wang, P ^a   Shen, W ^a   Winfree, K B ^a   Smyth, E N ^a   Boye, M E ^a   John, W ^a   Brodowicz, T ^b   Belani, C P ^c  

^a ELI LILLY AND COMPANY   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Lung cancer symptom scale; Maintenance therapy; Non squamous NSCLC; Patient reported symptoms; Pemetrexed; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; FOLIC ACID; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; AVERAGE SYMPTOM BURDEN INDEX; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HAZARD RATIO; HEALTH STATUS; HIGH SYMPTOM BURDEN SCALE; HISTOPATHOLOGY; HUMAN; LOW SYMPTOM BURDEN SCALE; LUNG CANCER SYMPTOM SCALE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; RATING SCALE; SEX DIFFERENCE; SMOKING; SYMPTOMATOLOGY; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

EID: 84878447147     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt123     Document Type: Article

References (40)

1. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 2004; 11: 559-595.
2. Schiller JH, Harrington D, Belani CP et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-small cell lung cancer Version 3.2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl (14 August 2012, date last accessed).
5. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005; 10(Suppl 3): 1-10.
6. Azzoli CG, Baker S, Termin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
7. Gridelli C, Maione P, Rossi A et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 2009; 14: 137-147.
8. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591-598.
9. Pérol M. Maintenance therapy in non-small-cell lung cancer-review of rationale, clinical need and available data. Eur Respir Dis 2010; 6: 70-75.
10. Owonikoko TK, Ramalingam SS, Belani CP. Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clin Cancer Res 2010; 16: 2496-2504.
11. Pennell NA. Selection of chemotherapy for patients with advanced non-small cell lung cancer. Cleve Clin J Med 2012; 79(electronic Suppl 1): eS46-eS50.
12. Tarhini AA, Argiris A. Maintenance therapy for advanced-non small cell lung cancer. Open Lung Cancer J 2010; 3: 73-79.
13. Belani CP, Barstis J, Perry MC et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21: 2933-2939.
14. Brodowicz T, Krzakowski M, Zwitter M et al. Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced nonsmall cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-163.
15. Westeel V, Quoix E, Moro-Sibilot D et al. French Thoracic Oncology Collaborative Group (GCOT). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 499-506.
16. Takeda K, Hida T, Sato T et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010; 28: 753-760.
17. Mok TS, Wu YL, Yu CJ et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced nonsmall-cell lung cancer. J Clin Oncol 2009; 27: 5080-5087.
18. Miller VA, O'Connor P, Soh C et al. for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(Suppl): abstr LBA8002.
19. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
20. Paz-Ares L, de Marinis F, Dediu M et al. PARAMOUNT: final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo ( plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30(Suppl): abstr LBA7507.
21. Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN Investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
22. D'Addario G, Felip E. ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(Suppl 4): 68-70.
23. Azzoli CG, Temin S, Giaccone G. 2011 Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract 2012; 8: 63-66.
24. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 5116-5123.
25. Stinchcombe TE, Socinski MA. Treatment paradigms for advanced stage nonsmall cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 2009; 4: 243-250.
26. Socinski MA, Morris DE, Masters GA et al. American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123(1 Suppl): 226S-243S.
27. Gotay CC, Kawamoto CT, Bottomley A et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008; 26: 1355-1363.
28. Quinten C, Coens C, Mauer M et al. EORTC Clinical Groups. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009; 10: 865-871.
29. Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 2006; 14: 999-1011.
30. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994; 12: 608-616.
31. Sprangers MA. Quality-of-life assessment in oncology. Achievements and challenges. Acta Oncol 2002; 41: 229-237.
32. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
33. Wang P, Bowman L, Shen W et al. The lung cancer symptom scale (LCSS) as a prognostic indicator of overall survival in malignant pleural mesothelioma (MPM) patients: post hoc analysis of a phase III study. J Clin Oncol 2012; 30 (Suppl): abstr 7075.
34. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253-263.
35. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
36. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
37. Hollen PJ, Gralla RJ, Kris MG. An overview of the lung cancer symptom scale. In Gralla RJ, Moinpour CM (eds), Assessing Quality of Life in Patients with Lung Cancer: A Guide for Clinicians. New York, NY: NCM Publishers 1995; 57-63 (Monograph, Quality of Life Symposium, 7th World Conference on Lung Cancer, Colorado Springs, Colorado, June1994).
38. Selvin S. Statistical Analysis of Epidemiologic Data. New York, NY: Oxford University Press 1996; 213-214.
39. Edelman MJ, Le Chevalier T, Soria JC. Maintenance therapy and advanced non- small-cell lung cancer: a skeptic's view. J Thorac Oncol 2012; 7: 1331-1336.
40. Perol M, Chouaid C, Milleron BJ et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010; 28(Suppl): abstr 7507.